Last Updated : May 20, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area Sort ascending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Actemra | tocilizumab | Giant cell arteritis (GCA) | Reimburse with clinical criteria and/or conditions | Complete | ||
| TBC | pegcetacoplan | Geographic atrophy secondary to age-related macular degeneration | Pending | |||
| N/A | enzalutamide | Genito-urinary cancer (prostate cancer) | Open for Stakeholder Input | |||
| Spevigo | spesolimab | generalized pustular psoriasis (GPP) | Pending | |||
| TBC | rozanolixizumab | Generalized myasthenia gravis (gMG). | Pending | |||
| Vyvgart | efgartigimod alfa | Generalized myasthenia gravis (gMG) | Reimburse with clinical criteria and/or conditions | Complete | ||
| TBC | zilucoplan | Generalized myasthenia gravis (gMG) | Suspended | |||
| Ultomiris | ravulizumab | Generalized Myasthenia Gravis | Pending | |||
| Lynparza | olaparib | gBRCAm, HER2-negative high-risk early breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| VPRIV | Velaglucerase alfa | Gaucher Disease | List with clinical criteria and/or conditions | Complete |
Last Updated : May 20, 2024